Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC 50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
性状
Solid
IC50 & Target[1][2]
IC50: 19.59 nM/L (insulin receptor)
体外研究(In Vitro)
Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L.Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells. has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot Analysis
体内研究(In Vivo)
Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisture and light, under nitrogenPowder -80°C 2 years;-20°C 1 ye
ClinicalTrial
参考文献
[1]. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.[2]. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul